Tempest Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Tempest Therapeutics

11/05/2023 14:01

* Tempest Therapeutics Inc  TPST.OQ  reported a quarterly
adjusted
loss of 55 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 64 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tempest Therapeutics Inc's reported EPS for the quarter
was a
loss of 55 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Tempest Therapeutics Inc shares had fallen by 11.2% this
quarter and gained 79.1% so far this year.
    * The company reported a quarterly loss of $7.64 million.
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $14.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.64          -0.55          Beat
 Dec. 31 2022      -0.76          -0.63          Beat
 Sep. 30 2022      -0.80          -0.66          Beat
 Jun. 30 2022      -0.92          -0.79          Beat